explore -WSS

explore

author：fashion 2025-08-23 04:58:04 - browse：2

An already record-setting summer heat wave will continue through August and will put more than 51 million Americans at risk of health impacts, according to new data from federal health officials. Mario Tama/Getty Images

WASHINGTON — An already record-setting summer heat wave will continue through August and will put more than 51 million Americans at risk of health impacts, according to new data from federal health officials.

Most of those vulnerable people live in 26 states and are expected to have at least five extreme heat days this month. Among the highest-risk counties, roughly 45% have high levels of uninsured adults and children and 18% have high senior populations, according to a relatively new monthly report drafted by the Health and Human Services Department’s two-year-old climate change office.

The southwestern regions of California, Arizona, and Texas and a swath of the Northwest including rural Idaho and Montana could see half of the month at dangerous heat levels. There will be fewer extreme heat days for most of the East Coast after record temperatures and unprecedented wildfire smog earlier in the summer, but it is still the hottest summer on record across the nation.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： PhRMA lawsuit over Medicare drug price negotiation tossed

WSS

Hundreds died while taking an arthritis drug, but nobody alerted patients

Drug companies' payments and gifts affect physicians' prescribing

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

Depression: FDA OKs Otsuka Pharmaceuticals digital therapeutic

Alzheimer's risk factor APOE4 may be a distinct form of the disease

Medicare Advantage 2025 payments will dip, Biden administration says

leisure time

explore

knowledge

What does generative AI mean for health care? We asked experts

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

Drug repurposing or repositioning? The language matters

Florida Supreme Court upholds state's abortion ban

Cancer drug shortages should be causing more outrage

How digital tools helped lower hypertension in marginalized patients

The high cost of giving birth even with insurance

First Opinion on colorectal cancer screening: letter and response

At least 13 dead in Texas as scorching temps continue

'Revelatory' study finds a smoking impact that remains after quitting

Wikipedia

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

Key House Republican on health care plans exit from Congress

Trial using CRISPR to edit HIV out of cells disappoints

Readout Newsletter: Biogen, Eisai, Aardvark Therapeutics, etc.

A disappointing year of Humira biosimilars

Depression: FDA OKs Otsuka Pharmaceuticals digital therapeutic

leisure time

knowledge

focus

hotspot